Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
126.9 USD | -8.06% | -2.54% | +2.66% |
05:26pm | Morgan Stanley Adjusts DexCom's Price Target to $132 From $122 | MT |
04:56pm | Canaccord Genuity Adjusts Price Target on DexCom to $145 From $144 | MT |
Evolution of the average Target Price on DexCom, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering DexCom, Inc.
BTIG | |
UBS | |
Citigroup | |
RBC Capital Markets | |
TD Cowen | |
Canaccord Genuity | |
Leerink Partners | |
Bernstein | |
Raymond James | |
Piper Sandler | |
Wells Fargo Securities | |
Morgan Stanley | |
Oppenheimer | |
BofA Securities | |
Stifel Nicolaus | |
Baird | |
Barclays | |
Cowen | |
Wolfe Research | |
JPMorgan Chase | |
Jefferies & Co. | |
SVB Leerink | |
Haywood Securities | |
Berenberg Bank | |
Guggenheim | |
Atlantic Equities |
EPS Revisions
- Stock Market
- Equities
- DXCM Stock
- Consensus DexCom, Inc.